WuXi AppTec looks to unload its Philadelphia manufacturing sites and WuXi Biologics slows its rapid expansion in the U.S. as ...
Pharmaceutical Technology on MSN4d
WuXi debates sale of pharma operations as BIOSECURE Act advancesWuXi is considering the sale of some US and European operations to mitigate the impact of upcoming restrictions.
Ahead of the BIOSECURE Act, WuXi AppTec is in talks to sell its Philadelphia-based cell and gene therapy unit, and WuXi ...
As the BIOSECURE Act works its way through the U.S. legislative branch, two companies named in the bill are reportedly ...
Drugmakers have been targeted on national security grounds and could lose customers if Congress passes Biosecure Act ...
The current status of the Biosecure Act is that it was passed ​ by the US House of Representatives on Sep 9, with a vote of ...
WuXi Biologics is expected to report a more modest pace of top-line expansion and lower profit margins in fiscal 2024. See ...
WuXi Biologics and WuXi AppTec are discussing the potential sale of some of their manufacturing units as the BIOSECURE Act looms in the background, as per a news report. WuXi AppTec has put its ...
The Financial Times reported Thursday that WuXi AppTec is looking to sell its cell and gene therapy manufacturing unit, with facilities in Philadelphia, while WuXi Biologics wants to offload some of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback